|
| Press Releases |
|
 |
|
| Friday, May 26, 2023 |
|
|
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma |
| These data will be presented on Monday, June 5 at 11:54 a.m. Central Daylight Time during an oral abstract session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #4502). more info >> |
|
| Thursday, May 25, 2023 |
|
|
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria |
| Eisai Co., Ltd. has announced that it will grant a total of 625 million yen to the Global Health Innovative Technology Fund ("GHIT Fund") to fund the third phase of its activities, which will take place in the five-year period from FY2023 to FY2027. more info >> |
|
| Wednesday, May 24, 2023 |
|
|
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023 |
| Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO23), which is taking place virtually and in-person in Chicago, Illinois from June 2 to 6. more info >> |
|
|
米国臨床腫瘍学会年次総会におけるエーザイのがん領域の製品・開発品に関する発表について |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、2023年6月2日から6日まで米国イリノイ州シカゴおよびバーチャル形式で開催される「米国臨床腫瘍学会（American Society of Clinical Oncology：ASCO）年次総会」（2023 ASCO Annual Meeting）において、当社のがん領域における製品・開発品の様々ながん種における最新知見を発表することをお知らせします。 more info >> |
|
| Saturday, May 20, 2023 |
|
|
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Great Britain |
| Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has submitted a Marketing Authorization Application (MAA) for lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody, for the treatment of early Alzheimer's disease (mild cognitive impairment due to Alzheimer's disease (AD) and mild AD dementia) with confirmed amyloid pathology in the brain, to the UK Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain. more info >> |
|
| Monday, May 22, 2023 |
|
|
エーザイ、抗アミロイドβプロトフィブリル抗体「レカネマブ」について、英国（北アイルランドを除く）において早期アルツハイマー病に係る販売承認申請を提出 |
| エーザイ株式会社とバイオジェン・インクは、このたび、英国（北アイルランドを除く）において、 エーザイが抗アミロイドβ（Aβ）プロトフィブリル抗体レカネマブ（一般名）について、脳内 アミロイド病理が確認された早期アルツハイマー病（アルツハイマー病（AD）による軽度認知障害および軽度認知症）に係る販売承認申請（MAA）を、英国医薬品医療製品規制庁（MHRA）に提出したことをお知らせします。 more info >> |
|
| Wednesday, May 17, 2023 |
|
|
エーザイ、臨床第III相Clarity AD試験データを用いた、日本における「レカネマブ」の社会的価値について、査読学術専門誌Neurology and Therapy誌に掲載 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、このたび、アルツハイマー病（AD）による軽度認知障害（MCI）および軽度AD（総称して早期ADと定義）当事者様に対する抗アミロイドβ（Aβ）プロトフィブリル*抗体レカネマブ（一般名、米国ブランド名「LEQEMBITM」）の日本の医療システム下における社会的価値をシミュレーションした結果が査読学術専門誌Neurology and Therapy誌に掲載されたことをお知らせします。 more info >> |
|
| Tuesday, May 16, 2023 |
|
|
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (brand name in the U.S.: LEQEMBI), an investigational anti-amyloid beta (Abeta) protofibril* antibody, for the treatment of early Alzheimer's disease (mild cognitive impairment due to Alzheimer's disease (AD) and mild AD dementia) with confirmed amyloid pathology in the brain. more info >> |
|
| Monday, May 8, 2023 |
|
|
Eisai Enters Into Joint Development Agreement with Blissbio for Antibody Drug Conjugate BB-1701 with Option Rights for Strategic Collaboration |
| Eisai Co., Ltd. announced today that it has entered into a joint development agreement with Bliss Biopharmaceutical (Hangzhou) Co., Ltd., for BB-1701, an antibody-drug conjugate (ADC) with option rights for a strategic collaboration. more info >> |
|
|
エーザイ、抗体薬物複合体BB-1701について、BlissBioと戦略的提携に向けたオプション権を有する共同開発契約を締結 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、抗体薬物複合体（Antibody-Drug Conjugate：ADC）である BB-1701 について、Bliss Biopharmaceutical(Hangzhou) Co., Ltd.（本社：中国浙江省、以下 BlissBio）と戦略的提携に向けたオプション権を有する共同開発契約を締結したことをお知らせします。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Asia Summit on Global Health and Hong Kong International Medical and Healthcare Fair Wrap Up Successfully
May 28, 2025 23:29 HKT/SGT
|
|
|
Global Leaders Gather for XIII International Meeting on International Cooperation
May 28, 2025 21:30: JST
|
|
|
Modern Dental Group's Thai Subsidiary Hexa Ceram Held 30th Anniversary Celebration and Dental Symposium
May 28, 2025 21:30 HKT/SGT
|
|
|
Asia Summit on Global Health and Hong Kong International Medical and Healthcare Fair Wrap Up Successfully
May 28, 2025 20:57: JST
|
|
|
Global Leaders Gather for XIII International Meeting on International Cooperation
May 28, 2025 20:30 HKT/SGT
|
|
|
SAPPE Makes a Global Splash in the Beverage Market, Unveils Global Campaign "Life's too Short, You Gotta Chew" at THAIFEX - ANUGA ASIA 2025
May 28, 2025 18:00 HKT/SGT
|
|
|
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China
May 28, 2025 17:45 JST
|
|
|
現代牙科集團泰國公司Hexa Ceram舉辦三十周年慶典暨牙科論壇
May 28, 2025 16:30 HKT/SGT
|
|
|
现代牙科集团泰国公司Hexa Ceram举办三十周年庆典暨牙科论坛
May 28, 2025 16:12 HKT/SGT
|
|
|
三菱重工、2024事業計画推進状況について発表
May 28, 2025 16:05: JST
|
|
|
GK Software becomes a Fujitsu company
May 28, 2025 15:33 JST
|
|
|
GMG Announces Internal G(R) Lubricant Testing Results Showing 10% Fuel Savings and 33% Reduction in Particulate Emissions
May 28, 2025 08:29 HKT/SGT
|
|
|
Spotlight: Sunny Nandwani, Founder & CEO, Acuver Consulting Inc.
May 27, 2025 22:30 HKT/SGT
|
|
|
聯想控股旗下君聯資本及聯想之星共同投資企業派格生物醫藥在港交所成功上市
May 27, 2025 22:10 HKT/SGT
|
|
|
联想控股旗下君联资本及联想之星共同投资企业派格生物医药在港交所成功上市
May 27, 2025 21:41 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
